Biomaterial Database

Antithrombotic therapy of acute stroke: thrombolytic agents. 1997

G J del Zoppo

Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037, USA.

Following the initial report of the clinical use of plasminogen activators (PAs) in cerebrovascular thrombosis in 1958, interest in the efficacy of this approach accelerated only when the need for acute intervention in stroke was recognized. The use of PAs in acute ischemic stroke is based on the observation that approximately 80-90% of focal cerebral ischemic events presenting as strokes within 8 hr of symptom onset are due to atherothrombotic and embolic occlusions.

UI	MeSH Term	Description	Entries
D002340	Carotid Artery Diseases	Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.	Carotid Atherosclerosis,Common Carotid Artery Disease,Internal Carotid Artery Disease,Arterial Diseases, Carotid,Arterial Diseases, Common Carotid,Arterial Diseases, External Carotid,Arterial Diseases, Internal Carotid,Atherosclerotic Disease, Carotid,Carotid Artery Disorders,Carotid Atherosclerotic Disease,Common Carotid Artery Diseases,External Carotid Artery Diseases,Internal Carotid Artery Diseases,Arterial Disease, Carotid,Artery Disease, Carotid,Artery Diseases, Carotid,Artery Disorder, Carotid,Artery Disorders, Carotid,Atherosclerotic Diseases, Carotid,Carotid Arterial Disease,Carotid Arterial Diseases,Carotid Artery Disease,Carotid Artery Disorder,Carotid Atheroscleroses,Carotid Atherosclerotic Diseases,Disorders, Carotid Artery
D002543	Cerebral Hemorrhage	Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.	Brain Hemorrhage, Cerebral,Cerebral Parenchymal Hemorrhage,Hemorrhage, Cerebral,Intracerebral Hemorrhage,Hemorrhage, Cerebrum,Brain Hemorrhages, Cerebral,Cerebral Brain Hemorrhage,Cerebral Brain Hemorrhages,Cerebral Hemorrhages,Cerebral Parenchymal Hemorrhages,Cerebrum Hemorrhage,Cerebrum Hemorrhages,Hemorrhage, Cerebral Brain,Hemorrhage, Cerebral Parenchymal,Hemorrhage, Intracerebral,Hemorrhages, Cerebral,Hemorrhages, Cerebral Brain,Hemorrhages, Cerebral Parenchymal,Hemorrhages, Cerebrum,Hemorrhages, Intracerebral,Intracerebral Hemorrhages,Parenchymal Hemorrhage, Cerebral,Parenchymal Hemorrhages, Cerebral
D002546	Ischemic Attack, Transient	Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	Brain Stem Ischemia, Transient,Cerebral Ischemia, Transient,Crescendo Transient Ischemic Attacks,Transient Ischemic Attack,Anterior Circulation Transient Ischemic Attack,Brain Stem Transient Ischemic Attack,Brain TIA,Brainstem Ischemia, Transient,Brainstem Transient Ischemic Attack,Carotid Circulation Transient Ischemic Attack,Posterior Circulation Transient Ischemic Attack,TIA (Transient Ischemic Attack),Transient Ischemic Attack, Anterior Circulation,Transient Ischemic Attack, Brain Stem,Transient Ischemic Attack, Brainstem,Transient Ischemic Attack, Carotid Circulation,Transient Ischemic Attack, Posterior Circulation,Transient Ischemic Attack, Vertebrobasilar Circulation,Transient Ischemic Attacks, Crescendo,Vertebrobasilar Circulation Transient Ischemic Attack,Attack, Transient Ischemic,Attacks, Transient Ischemic,Brainstem Ischemias, Transient,Cerebral Ischemias, Transient,Ischemia, Transient Brainstem,Ischemia, Transient Cerebral,Ischemias, Transient Brainstem,Ischemias, Transient Cerebral,Ischemic Attacks, Transient,TIA, Brain,TIAs (Transient Ischemic Attack),Transient Brainstem Ischemia,Transient Cerebral Ischemia,Transient Cerebral Ischemias,Transient Ischemic Attacks
D005343	Fibrinolytic Agents	Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.	Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208	Acute Disease	Disease having a short and relatively severe course.	Acute Diseases,Disease, Acute,Diseases, Acute
D012171	Retinal Vessels	The blood vessels which supply and drain the RETINA.	Pecten Oculi,Retinal Vasculature,Retinal Blood Vessels,Retinal Blood Vessel,Retinal Vasculatures,Retinal Vessel,Vasculature, Retinal,Vessel, Retinal,Vessel, Retinal Blood
D014715	Vertebrobasilar Insufficiency	Localized or diffuse reduction in blood flow through the vertebrobasilar arterial system, which supplies the BRAIN STEM; CEREBELLUM; OCCIPITAL LOBE; medial TEMPORAL LOBE; and THALAMUS. Characteristic clinical features include SYNCOPE; lightheadedness; visual disturbances; and VERTIGO. BRAIN STEM INFARCTIONS or other BRAIN INFARCTION may be associated.	Basilar Artery Insufficiency,Basilar Artery Stenosis,Vertebral Artery Insufficiency,Vertebral Artery Stenosis,Basilar Artery Ischemia,Basilar Insufficiency,Vertebral Artery Ischemia,Vertebro-Basilar Insufficiency,Vertebro-Basilar Ischemia,Vertebrobasilar Dolichoectasia,Vertebrobasilar Ischemia,Artery Insufficiencies, Basilar,Artery Insufficiencies, Vertebral,Artery Insufficiency, Basilar,Artery Insufficiency, Vertebral,Artery Ischemia, Basilar,Artery Ischemia, Vertebral,Artery Ischemias, Basilar,Artery Ischemias, Vertebral,Artery Stenoses, Basilar,Artery Stenoses, Vertebral,Artery Stenosis, Basilar,Artery Stenosis, Vertebral,Basilar Artery Insufficiencies,Basilar Artery Ischemias,Basilar Artery Stenoses,Basilar Insufficiencies,Dolichoectasia, Vertebrobasilar,Dolichoectasias, Vertebrobasilar,Insufficiencies, Basilar,Insufficiencies, Basilar Artery,Insufficiencies, Vertebral Artery,Insufficiencies, Vertebro-Basilar,Insufficiencies, Vertebrobasilar,Insufficiency, Basilar,Insufficiency, Basilar Artery,Insufficiency, Vertebral Artery,Insufficiency, Vertebro-Basilar,Insufficiency, Vertebrobasilar,Ischemia, Basilar Artery,Ischemia, Vertebral Artery,Ischemia, Vertebro-Basilar,Ischemia, Vertebrobasilar,Ischemias, Basilar Artery,Ischemias, Vertebral Artery,Ischemias, Vertebro-Basilar,Ischemias, Vertebrobasilar,Stenoses, Basilar Artery,Stenoses, Vertebral Artery,Stenosis, Basilar Artery,Stenosis, Vertebral Artery,Vertebral Artery Insufficiencies,Vertebral Artery Ischemias,Vertebral Artery Stenoses,Vertebro Basilar Insufficiency,Vertebro Basilar Ischemia,Vertebro-Basilar Insufficiencies,Vertebro-Basilar Ischemias,Vertebrobasilar Dolichoectasias,Vertebrobasilar Insufficiencies,Vertebrobasilar Ischemias
D017322	Clinical Trials, Phase II as Topic	Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.	Drug Evaluation, FDA Phase 2 as Topic,Drug Evaluation, FDA Phase II as Topic,Evaluation Studies, FDA Phase 2 as Topic,Evaluation Studies, FDA Phase II as Topic